在儿科眼科医学的基因疗法
Alejandra Daruich1,2, Matthieu P Robert1,3, Dominique Bremond-Gignac1,2
1Ophthalmology Department, Necker-Enfants Malades University Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris Cité University, Paris, France.
Frontiers in ophthalmology
|July 10, 2024
概括
沃雷基因pararvovec,第一个基因治疗遗传性视网膜发育不良 (IRD),在儿童中显示出希望. 目前正在进行的研究探索了对视力障碍的儿科眼科医学的进一步基因治疗应用.
科学领域:
- 眼科医生 眼科 眼科
- 遗传学 遗传学 是一个
- 医学研究 医学研究
背景情况:
- 遗传儿科眼睛疾病导致显著的视力丧失.
- 沃雷基因 neparvovec 是第一个被批准的基因疗法,用于遗传性视网膜发育不良 (IRD).
- 在儿童早期使用voretigene neparvovec证明了安全性和有效性.
研究的目的:
- 审查儿童遗传视网膜变症的基因疗法的最新进展.
- 讨论正在进行的研究和关于幼儿基因治疗的未解答问题.
- 探索儿童眼科医学的各种基因治疗方法.
主要方法:
- 对最近报告的文献综述.
- 对正在进行的临床研究进行分析.
- 对儿科眼部疾病的基因治疗现有知识的综合.
主要成果:
- 沃雷特基因 neparvovec 是一种安全且耐受良好的治疗IRD.
- 对儿童的基因疗法的早期干预产生了令人鼓舞的疗效.
- 几种有前途的基因治疗方法正在调查中.
结论:
- 基因疗法在治疗儿科遗传眼病方面开辟了新的前沿.
- 需要进一步的研究来解决与早期儿童基因疗法相关的具体问题.
- 基因治疗在儿科眼科医学的领域正在迅速发展.
相关概念视频
00:59Gene Therapy
25.4K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
25.4K
01:22iPS Cell Differentiation
2.7K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
2.7K